메뉴 건너뛰기




Volumn 90, Issue 12, 2015, Pages 1099-1105

Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; ANTINEOPLASTIC AGENT;

EID: 84954377274     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24198     Document Type: Article
Times cited : (58)

References (36)
  • 1
    • 40449092927 scopus 로고    scopus 로고
    • Evaluation of a comprehensive transcranial Doppler screening program for children with sickle cell anemia
    • McCarville MB, Goodin GS, Fortner G, et al. Evaluation of a comprehensive transcranial Doppler screening program for children with sickle cell anemia. Pediatr Blood Cancer 2008;50:818-821.
    • (2008) Pediatr Blood Cancer , vol.50 , pp. 818-821
    • McCarville, M.B.1    Goodin, G.S.2    Fortner, G.3
  • 2
    • 84927521781 scopus 로고    scopus 로고
    • Implementation of transcranial Doppler ultrasonography screening and primary stroke prevention in urban and rural sickle cell disease populations
    • Hussain S, Nichols F, Bowman L, et al. Implementation of transcranial Doppler ultrasonography screening and primary stroke prevention in urban and rural sickle cell disease populations. Pediatr Blood Cancer 2014;8:219-223.
    • (2014) Pediatr Blood Cancer , vol.8 , pp. 219-223
    • Hussain, S.1    Nichols, F.2    Bowman, L.3
  • 3
    • 15444348891 scopus 로고    scopus 로고
    • Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler
    • Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997;42:699-704.
    • (1997) Ann Neurol , vol.42 , pp. 699-704
    • Adams, R.J.1    McKie, V.C.2    Carl, E.M.3
  • 4
    • 0032474692 scopus 로고    scopus 로고
    • Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
    • Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
    • (1998) N Engl J Med , vol.339 , pp. 5-11
    • Adams, R.J.1    McKie, V.C.2    Hsu, L.3
  • 5
    • 44649195866 scopus 로고    scopus 로고
    • The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia
    • Hankins JS, Fortner GL, McCarville MB, et al. The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. Br J Haematol 2008;142:94-99.
    • (2008) Br J Haematol , vol.142 , pp. 94-99
    • Hankins, J.S.1    Fortner, G.L.2    McCarville, M.B.3
  • 6
    • 0026558470 scopus 로고
    • The use of transcranial ultrasonography to predict stroke in sickle cell disease
    • Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605-610.
    • (1992) N Engl J Med , vol.326 , pp. 605-610
    • Adams, R.1    McKie, V.2    Nichols, F.3
  • 7
    • 2342575535 scopus 로고    scopus 로고
    • Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study
    • Adams RJ, Brambilla DJ, Granger S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004;103:3689-3694.
    • (2004) Blood , vol.103 , pp. 3689-3694
    • Adams, R.J.1    Brambilla, D.J.2    Granger, S.3
  • 8
    • 20144386780 scopus 로고    scopus 로고
    • Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience
    • Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience. Blood 2005;105:2685-2690.
    • (2005) Blood , vol.105 , pp. 2685-2690
    • Gulbis, B.1    Haberman, D.2    Dufour, D.3
  • 9
    • 33750032587 scopus 로고    scopus 로고
    • Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease
    • Kratovil T, Bulas D, Driscoll MC, et al. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer 2006;47:894-900.
    • (2006) Pediatr Blood Cancer , vol.47 , pp. 894-900
    • Kratovil, T.1    Bulas, D.2    Driscoll, M.C.3
  • 10
    • 84938213406 scopus 로고    scopus 로고
    • Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort
    • Lagunju I, Brown BJ, Sodeinde O. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort. Pediatr Blood Cancer 2015;62:1587-1591.
    • (2015) Pediatr Blood Cancer , vol.62 , pp. 1587-1591
    • Lagunju, I.1    Brown, B.J.2    Sodeinde, O.3
  • 11
    • 38349127617 scopus 로고    scopus 로고
    • Use of hydroxyurea in prevention of stroke in children with sickle cell disease
    • Lefevre N, Dufour D, Gulbis B, et al. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood 2008;111:963-964.
    • (2008) Blood , vol.111 , pp. 963-964
    • Lefevre, N.1    Dufour, D.2    Gulbis, B.3
  • 12
    • 79955909191 scopus 로고    scopus 로고
    • Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG)
    • Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-1672.
    • (2011) Lancet , vol.377 , pp. 1663-1672
    • Wang, W.C.1    Ware, R.E.2    Miller, S.T.3
  • 13
    • 34547961356 scopus 로고    scopus 로고
    • Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia
    • Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007;110:1043-1047.
    • (2007) Blood , vol.110 , pp. 1043-1047
    • Zimmerman, S.A.1    Schultz, W.H.2    Burgett, S.3
  • 14
    • 1542376824 scopus 로고    scopus 로고
    • Chemical and functional analysis of hydroxyurea oral solutions
    • Heeney MM, Whorton MR, Howard TA, et al. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 2004;26:179-184.
    • (2004) J Pediatr Hematol Oncol , vol.26 , pp. 179-184
    • Heeney, M.M.1    Whorton, M.R.2    Howard, T.A.3
  • 15
    • 41349090417 scopus 로고    scopus 로고
    • Hydroxyurea for children with sickle cell disease
    • Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am 2008;55:483-501.
    • (2008) Pediatr Clin North Am , vol.55 , pp. 483-501
    • Heeney, M.M.1    Ware, R.E.2
  • 16
    • 84907016412 scopus 로고    scopus 로고
    • Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members
    • Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312:1033-1048.
    • (2014) JAMA , vol.312 , pp. 1033-1048
    • Yawn, B.P.1    Buchanan, G.R.2    Afenyi-Annan, A.N.3
  • 17
    • 0021286875 scopus 로고
    • Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia
    • Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-656.
    • (1984) J Clin Invest , vol.74 , pp. 652-656
    • Platt, O.S.1    Orkin, S.H.2    Dover, G.3
  • 18
    • 0034082976 scopus 로고    scopus 로고
    • Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin
    • Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000;109:322-327.
    • (2000) Br J Haematol , vol.109 , pp. 322-327
    • Hillery, C.A.1    Du, M.C.2    Wang, W.C.3    Scott, J.P.4
  • 19
    • 84867291404 scopus 로고    scopus 로고
    • Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice
    • Almeida CB, Scheiermann C, Jang JE, et al. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 2012;120:2879-2878.
    • (2012) Blood , vol.120 , pp. 2878-2879
    • Almeida, C.B.1    Scheiermann, C.2    Jang, J.E.3
  • 20
    • 59649100257 scopus 로고    scopus 로고
    • Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy
    • Lanaro C, Franco-Penteado CF, Albuqueque DM, et al. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 2009;85:235-242.
    • (2009) J Leukoc Biol , vol.85 , pp. 235-242
    • Lanaro, C.1    Franco-Penteado, C.F.2    Albuqueque, D.M.3
  • 21
    • 0036175090 scopus 로고    scopus 로고
    • Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease
    • Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002;116:436-444.
    • (2002) Br J Haematol , vol.116 , pp. 436-444
    • Gladwin, M.T.1    Shelhamer, J.H.2    Ognibene, F.P.3
  • 22
    • 0029025475 scopus 로고
    • Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia
    • Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
    • (1995) N Engl J Med , vol.332 , pp. 1317-1322
    • Charache, S.1    Terrin, M.L.2    Moore, R.D.3
  • 23
    • 0029982591 scopus 로고    scopus 로고
    • Hydroxyurea therapy in children severely affected with sickle cell disease
    • Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-828.
    • (1996) J Pediatr , vol.128 , pp. 820-828
    • Scott, J.P.1    Hillery, C.A.2    Brown, E.R.3
  • 24
    • 1542373662 scopus 로고    scopus 로고
    • Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
    • Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-2045.
    • (2004) Blood , vol.103 , pp. 2039-2045
    • Zimmerman, S.A.1    Schultz, W.H.2    Davis, J.S.3
  • 25
    • 84885158071 scopus 로고    scopus 로고
    • Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia
    • Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics 2013;132:677-683.
    • (2013) Pediatrics , vol.132 , pp. 677-683
    • Wang, W.C.1    Oyeku, S.O.2    Luo, Z.3
  • 26
    • 84869803950 scopus 로고    scopus 로고
    • Impact of hydroxyurea on clinical events in the BABY HUG trial
    • Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012;120:4304-4310.
    • (2012) Blood , vol.120 , pp. 4304-4310
    • Thornburg, C.D.1    Files, B.A.2    Luo, Z.3
  • 27
    • 84927796730 scopus 로고    scopus 로고
    • Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ thalassemia with IVS1-5(G->C) mutation
    • Dehury S, Purohit P, Patel S, et al. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ thalassemia with IVS1-5(G->C) mutation. Pediatr Blood Cancer 2014;62:1017-1023.
    • (2014) Pediatr Blood Cancer , vol.62 , pp. 1017-1023
    • Dehury, S.1    Purohit, P.2    Patel, S.3
  • 28
    • 84885767291 scopus 로고    scopus 로고
    • Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: A single-center experience in Brazil
    • Silva-Pinto AC, Angulo IL, Brunetta DM, et al. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: A single-center experience in Brazil. Sao Paulo Med J 2013;131:238-243.
    • (2013) Sao Paulo Med J , vol.131 , pp. 238-243
    • Silva-Pinto, A.C.1    Angulo, I.L.2    Brunetta, D.M.3
  • 29
    • 32544435138 scopus 로고    scopus 로고
    • Long-term hydroxyurea treatment in children with sickle cell disease: Tolerance and clinical outcomes
    • de Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: Tolerance and clinical outcomes. Haematologica 2006;91:125-128.
    • (2006) Haematologica , vol.91 , pp. 125-128
    • de Montalembert, M.1    Brousse, V.2    Elie, C.3
  • 30
    • 84954361970 scopus 로고    scopus 로고
    • Hydroxyurea therapy for children with sickle cell anemia in sub-Saharan Africa: Rationale and design of the REACH trial
    • in press.
    • McGann PT, Tshilolo L, Santos B, et al. Hydroxyurea therapy for children with sickle cell anemia in sub-Saharan Africa: Rationale and design of the REACH trial. Pediatr Blood Cancer, in press.
    • Pediatr Blood Cancer
    • McGann, P.T.1    Tshilolo, L.2    Santos, B.3
  • 31
    • 84862243355 scopus 로고    scopus 로고
    • Future directions of sickle cell disease research: The NIH perspective
    • Hoots WK, Shurin SB. Future directions of sickle cell disease research: The NIH perspective. Pediatr Blood Cancer 2012;59:353-357.
    • (2012) Pediatr Blood Cancer , vol.59 , pp. 353-357
    • Hoots, W.K.1    Shurin, S.B.2
  • 32
    • 84954374626 scopus 로고    scopus 로고
    • A call to action on sickle cell disease
    • Gotlib J, editor. The Hematologist, ASH News and Reports. Available at:. Accessed on July 6
    • Williams DA. A call to action on sickle cell disease. In: Gotlib J, editor. The Hematologist, ASH News and Reports. Available at: http://www.hematology.org/Thehematologist/President/4037.apx. Accessed on July 6, 2015.
    • (2015)
    • Williams, D.A.1
  • 33
    • 84862242929 scopus 로고    scopus 로고
    • A global perspective on sickle cell disease
    • Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer 2012;59:386-390.
    • (2012) Pediatr Blood Cancer , vol.59 , pp. 386-390
    • Aygun, B.1    Odame, I.2
  • 34
    • 84938739232 scopus 로고    scopus 로고
    • Clinical trial decision making in pediatric sickle cell disease: A qualitative study of perceived benefits and barriers to participation
    • Patterson CA, Chavez V, Mondestin V, et al. Clinical trial decision making in pediatric sickle cell disease: A qualitative study of perceived benefits and barriers to participation. J Pediatr Hematol Oncol 2015;37:415-422.
    • (2015) J Pediatr Hematol Oncol , vol.37 , pp. 415-422
    • Patterson, C.A.1    Chavez, V.2    Mondestin, V.3
  • 35
    • 84879232521 scopus 로고    scopus 로고
    • Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea
    • Lebensburger JD, Sidonio RF, DeBaun MR, et al. Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatr Blood Cancer 2013;60:1333-1337.
    • (2013) Pediatr Blood Cancer , vol.60 , pp. 1333-1337
    • Lebensburger, J.D.1    Sidonio, R.F.2    DeBaun, M.R.3
  • 36
    • 84856218422 scopus 로고    scopus 로고
    • Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial
    • Peters-Lawrence MH, Bell MC, Hsu LL, et al. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials 2012;33:291-297.
    • (2012) Contemp Clin Trials , vol.33 , pp. 291-297
    • Peters-Lawrence, M.H.1    Bell, M.C.2    Hsu, L.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.